ReviewCurrent osteoporosis reports2009
Bone markers in osteoporosis.
Review in Current osteoporosis reports, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Systematic Search and Modified e-Delphi Consensus for Serum Bone Biomarkers in Humans and Animal Models with SCI: Methodology.Topics in spinal cord injury rehabilitation · 2025Pooled it
- Osteoglycin and Bone-a Systematic Review.Current osteoporosis reports · 2019Pooled it
- Pharmacological treatment options for low Bone Mineral Density and secondary osteoporosis in Anorexia Nervosa: A systematic review of the literature.Journal of psychosomatic research · 2017Pooled it
- Effect of weight loss on bone health in overweight/obese postmenopausal breast cancer survivors.Breast cancer research and treatment · 2015Trial
- Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers.British journal of clinical pharmacology · 2013Trial
- Physical training increases osteoprotegerin in postmenopausal women.Journal of bone and mineral metabolism · 2012Trial
- Metabolic Disruption in Osteoporotic Sheep: Evaluating Vitamin D Deficiency and Cortisone Effects via Biochemical Markers.Nutrients · 2025Article
- Natural traditional Chinese medicine products: emerging therapeutic targets for the treatment of osteoporosis.Journal of orthopaedic surgery and research · 2025Review
- Does metabolic control of the disease related with bone turnover markers in children with type 1 diabetes mellitus in Turkey?BMC endocrine disorders · 2024Article
- Changes in bone mineral density in unconscious immobile stroke patients from the acute to chronic phases of brain diseases.Osteoporosis and sarcopenia · 2022Article
- Secondary Osteoporosis and Metabolic Bone Diseases.Journal of clinical medicine · 2022Review
- Comparison of Bone Mineral Density and Markers of Bone Turnover in Osteoporotic Women after 6-Month Treatment with Alendronate or Bazedoxifene: A Randomized Controlled Trial.Journal of bone metabolism · 2021Article
- Relationship between bone turnover markers and oxidative stress in children with type 1 diabetes mellitus.Pediatric research · 2021Article
- Osteoporosis in South-East Asian Countries.The Clinical biochemist. Reviews · 2020Review
- Effects of sodium glucose cotransporter 2 inhibitors on mineral metabolism in type 2 diabetes mellitus.Current opinion in nephrology and hypertension · 2019Review
- Treatment of osteoporosis with recombinant parathyroid hormone, utilisation of total body DXA to observe treatment effects on total body composition and factors determining response to therapy.Irish journal of medical science · 2019Article
- Association of bone turnover markers with glucose metabolism in Chinese population.Acta pharmacologica Sinica · 2017Article
- The association between bone turnover markers and kyphosis in community-dwelling older adults.Bone reports · 2016Article
- Sclerostin as a novel marker of bone turnover in athletes.Biology of sport · 2016Article
- Novel assessment tools for osteoporosis diagnosis and treatment.Current osteoporosis reports · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current biological markers of bone turnover have proven useful in improving fracture risk assessment and monitoring treatment efficacy in postmenopausal osteoporosis. Recent developments in the field of bone markers include 1) identification of new biochemical markers providing additional information on the complex pathways leading to bone fragility; 2) application of novel technologies such as proteomics for the discovery of novel markers; 3) automation and multiplexing for improving analytical performance and convenience; and 4) refinement of the clinical interpretation of markers. Currently, however, for the management of individual patients, their most established application is to monitor treatment efficacy and possibly to improve fracture risk assessment. The role of bone markers for improving adherence to therapy will need to be investigated in further studies. This brief review discusses these novel technological developments and the recent clinical data on the use of established and new markers in postmenopausal osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.